Skip to main content

Featured

CMHC Just Cut Its Housing Forecast — What It Means If You're Buying, Selling, or Renewing

  Published July 28, 2026 Canada Mortgage and Housing Corporation quietly downgraded its outlook for the rest of 2026 last week, and the new numbers are worth a look no matter which side of the housing market you're standing on. The federal housing agency's Summer 2026 update now calls for slower growth, softer home prices, fewer new builds and continued easing in rental markets right through the end of the year — with a split that leaves Ontario and B.C. looking a lot different from the Prairies and Quebec. Here's what's actually in the update, and what it means for your specific situation. What CMHC changed The agency's baseline call for 2026 is a Canadian economy growing at just 0.7%, with high borrowing costs, weak population growth and cautious buyers keeping a lid on demand even as affordability has technically improved. The practical result, nationally: Housing starts are expected to fall to about 241,400 units this year, down from 259,028 in 2025 Resale acti...
Post a Comment
Read more

article

Labels

Revolutionary Gene Therapy Restores Hearing in Deaf Toddler

 

In a remarkable medical breakthrough, an 18-month-old toddler named Opal Sandy has regained her hearing thanks to a pioneering gene therapy trial. Born deaf due to a rare genetic condition affecting the OTOF gene, which is responsible for producing a protein essential for hearing, Opal’s prospects for natural hearing were bleak. However, the innovative treatment at Cambridge University Hospitals in England has opened up a world of sound for her.

The procedure involved the infusion of a working copy of the OTOF gene into Opal’s right ear, a process that took a mere 16 minutes. Remarkably, within weeks, Opal began responding to loud noises, and after 24 weeks, she could hear whispers, indicating a near-normal level of hearing restoration.

Opal’s case is part of the Chord trial, which is recruiting more children from the UK, Spain, and the US to undergo similar treatment. The trial is being closely monitored, with participants followed up for five years to assess the long-term efficacy and safety of the therapy.

The success of this gene therapy is a beacon of hope for many suffering from genetic deafness, signaling the dawn of a new era in medical science where conditions once thought incurable are now within the realm of treatment. Opal’s story is not just a personal victory; it’s a milestone in genetic medicine, showcasing the incredible potential of gene therapy to change lives.

Labels:

Comments

Post a Comment